Evidence-Based Osteoporosis Care

Osteoporosis, Two-Volume Set

Volumn , Issue , 2008, Pages 1629-1649

  Kennel, Kurt A ^a   Swiglo, Brian A ^a   Montori, Victor M ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883963879     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012370544-0.50071-9     Document Type: Chapter

References (99)

1. Guyatt G.H. Evidence-based medicine. ACP J Club 1991, A-16.
2. Guyatt G.H., Rennie D. Users' guides to the medical literature. JAMA 1993, 270:2096-2097.
3. Guyatt G.H., Haynes R.B., Jaeschke R., Cook D.J., Greenhalgh T.M.M., Green L., Naylor C.D., Wilson M.M.F., Richardson W.S., Vm M., Bucher H. Introduction: The philosophy of evidence-based medicine. Users' Guides to the Medical Literature. A Manual for Evidence-Based Clinical Practice 2002, 3-11. AMA Press, Chicago, IL. G.H. Guyatt, D. Rennie (Eds.).
4. Dawson N.V., Arkes H.R. Systematic errors in medical decision making: Judgment limitations. J Gen Intern Med 1987, 2:183-187.
5. Kleerekoper M. Fluoride and the skeleton. Crit Rev Clin Lab Sci 1996, 33:139-161.
6. Briancon D., Meunier P.J. Treatment of osteoporosis with fluoride calcium and vitamin D. Orthop Clin North Am 1981, 12:629-648.
7. Rich C., Ensinck J. Effect of sodium fluoride on calcium metabolism of human beings. Nature 1961, 191:184-185.
8. Eriksen E.F., Mosekilde L., Melsen F. Effect of sodium fluoride calcium phosphate and vitamin D2 on trabecular bone balance and remodeling in osteoporotics. Bone 1985, 6:381-389.
9. Mithal A., Trivedi N., Gupta S.K., Kumar S., Gupta R.K. Radiological spectrum of endemic fluorosis: Relationship with calcium intake. Skeletal Radiol 1993, 22:257-261.
10. Riggs B.L., Hodgson S.F., O'Fallon W.M., Chao E.Y., Wahner H.W., Muhs J.M., Cedel S.L., Melton L.J. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990, 322:802-809.
11. Orcel P., de Vernejoul M.C., Prier A., Miravet L., Kuntz D., Kaplan G. Stress fractures of the lower limbs in osteoporotic patients treated with fluoride. J Bone Miner Res 1990, 5(Suppl 1):S191-S194.
12. Schnitzler C.M., Solomon L. Trabecular stress fractures during fluoride therapy for osteoporosis. Skeletal Radiol 1985, 14:276-279.
13. Haguenauer D., Welch V., Shea B., Tugwell P., Adachi J.D., Wells G. Fluoride for the treatment of postmenopausal osteoporotic fractures: A meta-analysis. Osteoporos Int 2000, 11:727-738.
14. Johnell O., Kanis J.A., Oden A., Johansson H., De Laet C., Delmas P., Eisman J.A., Fujiwara S., Kroger H., Mellstrom D., Meunier P.J., Melton L.J., O'Neill T., Pols H., Reeve J., Silman A., Tenenhouse A. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005, 20:1185-1194.
15. Melton L.J. Epidemiology of spinal osteoporosis. Spine 1997, 22:2S-11S.
16. Melton L.J., Atkinson E.J., Khosla S., Oberg A.L., Riggs B.L. Evaluation of a prediction model for long-term fracture risk. J Bone Miner Res 2005, 20:551-556.
17. De Laet C., Kanis J.A., Oden A., Johanson H., Johnell O., Delmas P., Eisman J.A., Kroger H., Fujiwara S., Garnero P., McCloskey E.V., Mellstrom D., Melton L.J., Meunier P.J., Pols H.A., Reeve J., Silman A., Tenenhouse A. Body mass index as a predictor of fracture risk: A meta-analysis. Osteoporos Int 2005, 16:1330-1338.
18. Kanis J.A., Borgstrom F., De Laet C., Johansson H., Johnell O., Jonsson B., Oden A., Zethraeus N., Pfleger B., Khaltaev N. Assessment of fracture risk. Osteoporos Int 2005, 16:581-589.
19. Kanis J.A., Johansson H., Johnell O., Oden A., De Laet C., Eisman J.A., Pols H., Tenenhouse A. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005, 16:737-742.
20. Kanis J.A., Johansson H., Oden A., Johnell O., De Laet C., Eisman J.A., McCloskey E.V., Mellstrom D., Melton L.J., Pols H.A., Reeve J., Silman A., Tenenhouse A.J. A family history of fracture and fracture risk: A meta-analysis. Bone 2004, 35:1029-1037.
21. Kanis J.A., Johansson H., Oden A., Johnell O., De Laet C., Melton I.L., Tenenhouse A., Reeve J., Silman A.J., Pols H.A., Eisman J.A., McCloskey E.V., Mellstrom D.A. Meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004, 19:893-899.
22. Kanis J.A., Johnell O., Oden A., Johansson H., De Laet C., Eisman J.A., Fujiwara S., Kroger H., McCloskey E.V., Mellstrom D., Melton L.J., Pols H., Reeve J., Silman A., Tenenhouse A. Smoking and fracture risk: A meta-analysis. Osteoporos Int 2005, 16:155-162.
23. Montori V.M., Devereaux P.J., Adhikari N.K., Burns K.E., Eggert C.H., Briel M., Lacchetti C., Leung T.W., Darling E., Bryant D.M., Bucher H.C., Schunemann H.J., Meade M.O., Cook D.J., Erwin P.J., Sood A., Sood R., Lo B., Thompson C.A., Zhou Q., Mills E., Guyatt G.H. Randomized trials stopped early for benefit: A systematic review. JAMA 2005, 294:2203-2209.
24. Montori V.M., Swiontkowski M.F., Cook D.J. Methodologic issues in systematic reviews and meta-analyses. Clin Orthop Relat Res 2003, 43-54.
25. Cranney A., Guyatt G., Griffith L., Wells G., Tugwell P., Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002, 23:570-578.
26. Cranney A., Tugwell P., Adachi J., Weaver B., Zytaruk N., Papaioannou A., Robinson V., Shea B., Wells G., Guyatt G. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002, 23:517-523.
27. Cranney A., Tugwell P., Wells G., Guyatt G. Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: Introduction and methodology. Endocr Rev 2002, 23:496-507.
28. Cranney A., Tugwell P., Zytaruk N., Robinson V., Weaver B., Adachi J., Wells G., Shea B., Guyatt G. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002, 23:524-528.
29. Cranney A., Tugwell P., Zytaruk N., Robinson V., Weaver B., Shea B., Wells G., Adachi J., Waldegger L., Guyatt G. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002, 23:540-551.
30. Cranney A., Wells G., Willan A., Griffith L., Zytaruk N., Robinson V., Black D., Adachi J., Shea B., Tugwell P., Guyatt G. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002, 23:508-516.
31. Haynes R.B., Devereaux P.J., Guyatt G.H. Physicians' and patients' choices in evidence based practice. BMJ 2002, 324:1350.
32. Papadimitropoulos E., Wells G., Shea B., Gillespie W., Weaver B., Zytaruk N., Cranney A., Adachi J., Tugwell P., Josse R., Greenwood C., Guyatt G. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002, 23:560-569.
33. Shea B., Wells G., Cranney A., Zytaruk N., Robinson V., Griffith L., Ortiz Z., Peterson J., Adachi J., Tugwell P., Guyatt G. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002, 23:552-559.
34. Wells G., Tugwell P., Shea B., Guyatt G., Peterson J., Zytaruk N., Robinson V., Henry D., O'Connell D., Cranney A. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002, 23:529-539.
35. Users' Guides to the Medical Literature. A Manual for Evidence-Based Clinical Practice 2002, AMA Press, Chicago, IL. G.H. Guyatt, D. Rennie (Eds.).
36. Guyatt G., Cook D.J., Devereaux P.J., Meade M., Straus S. Therapy. Users' Guides to the Medical Literature. A Manual for Evidence-Based Clinical Practice 2002, 55-79. AMA Press, Chicago, IL. G. Guyatt, D. Rennie (Eds.).
37. Schulz K.F., Grimes D.A. Allocation concealment in randomised trials: Defending against deciphering. Lancet 2002, 359:614-618.
38. Schulz K.F., Grimes D.A. Blinding in randomised trials: Hiding who got what. Lancet 2002, 359:696-700.
39. Montori V.M., Wang Y.G., Alonso-Coello P., Bhagra S. Systematic evaluation of the quality of randomized controlled trials in diabetes. Diabetes Care 2006, 29:1833-1838.
40. Devereaux P.J., Choi P.T., El-Dika S., Bhandari M., Montori V.M., Schunemann H.J., Garg A.X., Busse J.W., Heels-Ansdell D., Ghali W.A., Manns B.J., Guyatt G.H. An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding despite the failure to report these methods. J Clin Epidemiol 2004, 57:1232-1236.
41. Altman D.G., Dore C.J. Randomisation and baseline comparisons in clinical trials. Lancet 1990, 335:149-153.
42. Pocock S.J., Assmann S.E., Enos L.E., Kasten L.E. Subgroup analysis covariate adjustment and baseline comparisons in clinical trial reporting: Current practice and problems. Stat Med 2002, 21:2917-2930.
43. Schulz K.F., Chalmers I., Hayes R.J., Altman D.G. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995, 273:408-412.
44. Devereaux P.J., Manns B.J., Ghali W.A., Quan H., Lacchetti C., Montori V.M., Bhandari M., Guyatt G.H. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA 2001, 285:2000-2003.
45. Montori V.M., Bhandari M., Devereaux P.J., Manns B.J., Ghali W.A., Guyatt G.H. In the dark: The reporting of blinding status in randomized controlled trials. J Clin Epidemiol 2002, 55:787-790.
46. Montori V.M., Guyatt G.H. Intention-to-treat principle. CMAJ 2001, 165:1339-1341.
47. Walter S.D., Guyatt G., Montori V.M., Cook R., Prasad K. A new preference-based analysis for randomized trials can estimate treatment acceptability and effect in compliant patients. J Clin Epidemiol 2006, 59:685-696.
48. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., Chesnut C.H., Brown J., Eriksen E.F., Hoseyni M.S., Axelrod D.W., Miller P.D. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. [see comment]. JAMA 1999, 282:1344-1352.
49. Oxman A., Guyatt G., Cook D.J., Montori V.M. Summarizing the evidence. Users' Guides to the Medical Literature. A Manual for Evidence-Based Clinical Practice 2002, 155-173. AMA Press, Chicago, IL. G. Guyatt, D. Rennie (Eds.).
50. Oxman A.D., Guyatt G.H. A consumer's guide to subgroup analyses. Ann Intern Med 1992, 116:78-84.
51. Oxman A., Guyatt G. Summarizing the evidence-when to believe a subgroup analysis. Users' Guides to the Medical Literature. A Manual for Evidence-Based Clinical Practice 2002, 553-565. AMA Press, Chicago, IL. G. Guyatt, D. Rennie (Eds.).
52. Jackson R.D., LaCroix A.Z., Gass M., Wallace R.B., Robbins J., Lewis C.E., Bassford T., Beresford S.A., Black H.R., Blanchette P., Bonds D.E., Brunner R.L., Brzyski R.G., Caan B., Cauley J.A., Chlebowski R.T., Cummings S.R., Granek I., Hays J., Heiss G., Hendrix S.L., Howard B.V., Hsia J., Hubbell F.A., Johnson K.C., Judd H., Kotchen J.M., Kuller L.H., Langer R.D., Lasser N.L., Limacher M.C., Ludlam S., Manson J.E., Margolis K.L., McGowan J., Ockene J.K., O'Sullivan M.J., Phillips L., Prentice R.L., Sarto G.E., Stefanick M.L., Van Horn L., WactawskiWende J., Whitlock E., Anderson G.L., Assaf A.R., Barad D. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006, 354:669-683.
53. Montori V.M., Kleinbart J., Newman T.B., Keitz S., Wyer P.C., Moyer V., Guyatt G. Tips for learners of evidencebased medicine: 2. Measures of precision (confidence intervals). CMAJ 2004, 171:611-615.
54. Bischoff-Ferrari H.A., Dawson-Hughes B., Willett W.C., Staehelin H.B., Bazemore M.G., Zee R.Y., Wong J.B. Effect of vitamin D on falls: A meta-analysis. JAMA 2004, 291:1999-2006.
55. Shea B., Wells G., Cranney A., Zytaruk N., Robinson V., Griffith L., Ortiz Z., Peterson J., Adachi J., Tugwell P., Guyatt G. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002, 23:552-559.
56. Cauley J.A., Robbins J., Chen Z., Cummings S.R., Jackson R.D., LaCroix A.Z., LeBoff M., Lewis C.E., McGowan J., Neuner J., Pettinger M., Stefanick M.L., Wactawski-Wende J., Watts N.B. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA 2003, 290:1729-1738.
57. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
58. Gallagher J.C., Riggs B.L., Hamstra A., DeLuca H.F. Effect of estrogen therapy on calcium absorption and vitamin D metabolism in postmenopausal osteoporosis. Clin Res 1978, 26.
59. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary reference intakes: For calcium phosphorus magnesium vitamin D and fluoride 1997, National Academy Press, Washington, D.C.
60. Montori V.M., Permanyer-Miralda G., Ferreira-Gonzalez I., Busse J.W., Pacheco-Huergo V., Bryant D., Alonso J., Akl E.A., Domingo-Salvany A., Mills E., Wu P., Schunemann H.J., Jaeschke R., Guyatt G.H. Validity of composite end points in clinical trials. BMJ 2005, 330:594-596.
61. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J-Y., Hodsman A.B., Eriksen E.F., Ish- Shalom S., Genant H.K., Wang O., Mitlak B.H., Mellstrom D., Oefjord E.S., Marcinowska-Suchowierska E., Salmi J., Mulder H., Halse J., Sawicki A.Z. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
62. Seeley D.G., Browner W.S., Nevitt M.C., Genant H.K., Scott J.C., Cummings S.R. Which fractures are associated with low appendicular bone mass in elderly women?. Ann Intern Med 1991, 115:837-842.
63. Siris E.S., Harris S.T., Eastell R., Zanchetta J.R., Goemaere S., Diez-Perez A., Stock J.L., Song J., Qu Y., Kulkarni P.M., Siddhanti S.R., Wong M., Cummings S.R. Skeletal Effects of raloxifene after 8 years: Results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res 2005, 20:1514-1524.
64. Tonino R.P., Meunier P.J., Emkey R., Rodriguez- Portales J.A., Menkes C.J., Wasnich R.D., Bone H.G., Santora A.C., Wu M., Desai R., Ross P.D. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000, 85:3109-3115.
65. Kanis J.A., Johnell O., Oden A., Sembo I., Redlund-Johnell I., Dawson A., De Laet C., Jonsson B. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000, 11:669-674.
66. Hochberg M.C., Thompson D.E., Black D.M., Quandt S.A., Cauley J., Geusens P., Ross P.D., Baran D. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 2005, 20:971-976.
67. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., Rodriguez-Portales J.A., Downs R.W., Gupta J., Santora A.C., Liberman U.A. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-1199.
68. Ensrud K.E., Barrett-Connor E.L., Schwartz A., Santora A.C., Bauer D.C., Suryawanshi S., Feldstein A., Haskell W.L., Hochberg M.C., Torner J.C., Lombardi A., Black D.M. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004, 19:1259-1269.
69. Woo S.B., Hellstein J.W., Kalmar J.R. Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 144:753-761.
70. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., Pak C.Y. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
71. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C., Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001, 28:524-531.
72. Dowd R., Recker R.R., Heaney R.P. Study subjects and ordinary patients. Osteoporos Int 2000, 11:533-536.
73. DeLuca H.F. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004, 80:1689S-1696S.
74. Bischoff H.A., Borchers M., Gudat F., Duermueller U., Theiler R., Stahelin H.B., Dick W. In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J 2001, 33:19-24.
75. Sorensen O.H., Lund B., Saltin B., Lund B., Andersen R.B., Hjorth L., Melsen F., Mosekilde L. Myopathy in bone loss of ageing: Improvement by treatment with 1 alpha-hydroxycholecalciferol and calcium. Clin Sci (Lond) 1979, 56:157-161.
76. Bischoff-Ferrari H.A., Dietrich T., Orav E.J., Hu F.B., Zhang Y., Karlson E.W., Dawson-Hughes B. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y. Am J Clin Nutr 2004, 80:752-758.
77. Graafmans W.C., Ooms M.E., Hofstee H.M., Bezemer P.D., Bouter L.M., Lips P. Falls in the elderly: A prospective study of risk factors and risk profiles. Am J Epidemiol 1996, 143:1129-1136.
78. Bischoff H.A., Stahelin H.B., Dick W., Akos R., Knecht M., Salis C., Nebiker M., Theiler R., Pfeifer M., Begerow B., Lew R.A., Conzelmann M. Effects of vitamin D and calcium supplementation on falls: A randomized controlled trial. J Bone Miner Res 2003, 18:343-351.
79. Pfeifer M., Begerow B., Minne H.W., Abrams C., Nachtigall D., Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000, 15:1113-1118.
80. Tinetti M.E., Speechley M., Ginter S.F. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988, 319:1701-1707.
81. Weiner S.J. From research evidence to context: The challenge of individualizing care. ACP J Club 2004, 141:A11-A12.
82. Montori V.M. Evidence-based endocrinology: How far have we come?. Treat Endocrinol 2004, 3:1-10.
83. Guyatt G., Vist G., Falck-Ytter Y., Kunz R., Magrini N., Schunemann H. An emerging consensus on grading recommendations?. ACP J Club 2006, 144:A8-A9.
84. Gaston C.M., Mitchell G. Information giving and decision- making in patients with advanced cancer: A systematic review. Soc Sci Med 2005, 61:2252-2264.
85. Beaver K., Bogg J., Luker K.A. Decision-making role preferences and information needs: A comparison of colorectal and breast cancer. Health Expect 1999, 2:266-276.
86. Levinson W., Kao A., Kuby A., Thisted R.A. Not all patients want to participate in decision making. A national study of public preferences. J Gen Intern Med 2005, 20:531-535.
87. Montori V.M., Rothman R.L. Weakness in numbers. The challenge of numeracy in health care. JGIM 2005, 20:1071-1072.
88. Caro J.J., Ishak K.J., Huybrechts K.F., Raggio G., Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004, 15:1003-1008.
89. Cuddihy M.T., Gabriel S.E., Crowson C.S., Atkinson E.J., Tabini C., O'Fallon W.M., Melton L.J. Osteoporosis intervention following distal forearm fractures: A missed opportunity?. Arch Intern Med 2002, 162:421-426.
90. Cuddihy M.T., Gabriel S.E., Crowson C.S., O'Fallon W.M., Melton L.J. Forearm fractures as predictors of subsequent osteoporotic fractures. Osteoporos Int 1999, 9:469-475.
91. Kamel H.K., Hussain M.S., Tariq S., Perry H.M., Morley J.E. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med 2000, 109:326-328.
92. Ettinger B., Pressman A.R., Schein J., et al. Alendronate use among 812 women: Prevalence of gastrointestinal complaints non-compliance with patient instructions and discontinuation. J Managed Care Pharm 1998, 4:488-492.
93. Papaioannou A., Ioannidis G., Adachi J.D., Sebaldt R.J., Ferko N., Puglia M., Brown J., Tenenhouse A., Olszynski W.P., Boulos P., Hanley D.A., Josse R., Murray T.M., Petrie A., Goldsmith C.H. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 2003, 14:808-813.
94. Mauck K.F., Cuddihy M.T., Trousdale R.T., Pond G.R., Pankratz V.S., Melton L.J. The decision to accept treatment for osteoporosis following hip fracture: Exploring the woman's perspective using a stage-of-change model. Osteoporos Int 2002, 13:560-564.
95. Cuddihy M.T., Amadio P.C., Gabriel S.E., Pankratz V.S., Kurland R.L., Melton L.J. A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture. Osteoporos Int 2004, 15:695-700.
96. O'Connor A.M., Stacey D., Entwistle V., LlewellynThomas H., Rovner D., Holmes- Rovner M., Tait V., Tetroe J., Fiset V., Barry M., Jones J. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2003, CD001431.
97. Kanis J.A., Black D., Cooper C., Dargent P., Dawson- Hughes B., De Laet C., Delmas P., Eisman J., Johnell O., Jonsson B., Melton L., Oden A., Papapoulos S., Pols H., Rizzoli R., Silman A., Tenenhouse A. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 2002, 13:527-536.
98. Atkins D., Best D., Briss P.A., Eccles M., Falck-Ytter Y., Flottorp S., Guyatt G.H., Harbour R.T., Haugh M.C., Henry D., Hill S., Jaeschke R., Leng G., Liberati A., Magrini N., Mason J., Middleton P., Mrukowicz J., O'Connell D., Oxman A.D., Phillips B., Schunemann H.J., Edejer T.T., Varonen H., Vist G.E., Williams J.W., Zaza S. Grading quality of evidence and strength of recommendations. BMJ 2004, 328:1490.
99. A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996, 348:1329-1339.